BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

(d)On September 13, 2017, the Board of Directors of Bristol-Myers Squibb Company (the “Company”) elected Karen H. Vousden, Ph.D., 60, to serve as a member of the Board of Directors, effective January 1, 2018. The size of the Board of Directors was increased to eleven, effective January 1, 2018, in connection with Dr. Vousden’s election.

Dr. Vousden serves as Group Leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK. The Board of Directors has determined that Dr. Vousden is independent under the New York Stock Exchange Listing Standards and the independence standards adopted by the Board of Directors. Dr. Vousden will serve as a member of the Science and Technology Committee, effective January 1, 2018.

Dr. Vousden was not selected as a director to any arrangement or understanding between her and any other person. There are no related party transactions between the Company and Dr. Vousden.

Dr. Vousden will receive compensation for her services on the Board of Directors in accordance with the Company’s standard compensatory arrangement for non-employee directors, including an annual retainer of $100,000 and an annual award of deferred share units valued at $170,000 on the date of grant. In addition, she will receive an annual retainer of $15,000 for her service as a member of the Science and Technology Committee effective January 1, 2018.

A copy of the press release announcing Dr. Vousden’s election is attached to this report as Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.

Description

Press release dated September 13, 2017.


BRISTOL MYERS SQUIBB CO Exhibit
EX-99.1 2 s001877x1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1       Bristol-Myers Squibb Names Karen Vousden,…
To view the full exhibit click here

About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

An ad to help with our costs